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 Abstract
Introduction: The period of time elapsed after receiving a positive test result, has been previously 
associated with distress in BRCA1/2 carriers. However, there is a need for reliable instruments 
and prospective data on distress and perception of risk by those carriers, given the significant 
increase in demand for BRCA1/2 testing. 
Aim: To validate and implement in clinical practice, an instrument for the detection of distress 
and analysis of risk perception, in individuals that test positive for a BRCA1/2 test. 
Materials and Methods: We conducted a prospective study to design and test an instrument (Distress and Risk Perception 
Questionnaire-DRP) to evaluate distress and risk perception by BRCA1/2 carriers. Predictive factors for clinically relevant distress, 
were also explored.
Results: One hundred and seventy consecutive, newly diagnosed BRCA1/2 carriers were included (pre-test phase: 21 and test: 
149). Distress was measured with the distress thermometer (DT) and DRP, both applied, by telephone, one month after test 
disclosure. Clinically relevant distress was observed in 40% of the cases. Being a female (OR male vs female=0.37; 95%CI=0.10-
1.09) and index patient (OR index vs relative=3.93; 95%CI=1.13-18.37) were independent predictors for distress after adjusting 
for personal history of cancer. The risk perception was high and no significant correlation with distress was observed with either 
DT or DRP (Spearman correlation coefficient<0.1 and p>0.05 in both). 
Conclusion: DRP is a new scale, easy to administer by telephone, which measures distress and risk perception in BRCA1/2 
carriers. Gender and type of genetic screening (being an index patient or a relative) may play a role in the short-term emotional 
impact of a positive BRCA test result. 
 Resumo
Introdução: O distress identificado em portadores de mutações BRCA1/2 foi previamente 
associado ao período de tempo decorrido desde o conhecimento do resultado do teste. 
Atendendo ao aumento da procura para realizar testes genéticos, são necessários dados 
prospetivos sobre o distress e a perceção de risco nos portadores de variantes patogénicas 
BRCA1/2.
Objectivo: Desenvolver e validar um questionário dirigido para medir o distress e a perceção de risco em portadores de BRCA1/2.
Materiais e Métodos: Neste estudo, de carater prospetivo, foi elaborado e testado um instrumento (questionário de distress e 
perceção de Risco - DPR) que avalia o distress e a perceção de risco em portadores de BRCA1/2. Foram também explorados 
fatores preditivos para o distress clinicamente relevante.
Resultados: Foram analisados cento e setenta portadores de BRCA1/2 recém diagnosticados (21 na fase pré-teste e 149 na 
fase teste), identificados de forma consecutiva. Mediu-se o distress com o termómetro de distress (TD) e com o DPR, ambos 
aplicados através de entrevista telefónica, um mês após a comunicação dos resultados do teste genético. Em 40% dos casos 
observou-se distress clinicamente relevante; o género feminino (OR masculino vs feminino=0,37; 95%CI=0,10-1,09) e a situação 
Keywords





Cancro hereditário; portador 
BRCA; stresse psicológico; 
fatores preditivos; perceção 
de risco.
51S c r e e n i n g  f o r  D i s t r e s s  i n  B R C A 1 / 2  ca r r i e r s :  a  p r o s p e c t i v e  s t u d y  
de ser o primeiro familiar a ser testado (doente índex) (OR índex vs familiar=3,93; 95%CI=1,13-18,37) foram identificados como 
fatores preditores independentes para o distress. A perceção de risco individual e familiar foi alta e não se observou correlação 
significativa desta com o distress, medido tanto com o TD como com o DPR (coeficiente de correlação Spearman<0,1 e p>0,05 
em ambos).
Conclusão: O questionário DPR é uma escala nova, fácil de administrar por via telefónica, que mede o distress e a perceção de 
risco em portadores BCRA1/2. As doentes mulheres e a situação de primeiro familiar a ser testado (doente índex) são fatores 
preditores do impacto emocional, a curto prazo, de um resultado positivo no teste genético BCRA1/2.
 Introduction
Pathogenic mutations in BRCA1/2 genes explain 
most of the known cases of hereditary breast and 
ovarian cancer.1-3 These carriers are also at risk for 
prostate and pancreatic cancer and, for BRCA2 
carriers, also for gastric cancer, multiple myeloma 
and other neoplasia.4,5 Intensive surveillance, che-
moprevention and/or prophylactic surgeries are 
recommended to BRCA1/2 carriers with the main 
goal of preventing cancer morbidity and mortality.6 
Testing for BRCA1/2 pathogenic variants should 
be preceded by appropriate genetic counselling. 
During counselling, advantages and disadvantages of 
testing, including the possible adverse psychological 
outcomes should be discussed. Genetic counselling 
regarding BRCA1/2 testing is a complex process 
that may not always fulfil patients’ needs.7, 8 Even 
for index patients and their relatives with positive 
test results, uncertainty looms and is perceived as a 
limitation, justifying implementation of surveillance 
and preventive procedures.6, 9 Indeed,8 realizing its 
status as a BRCA1/2 carrier may have an emotional 
impact affecting the patient, her/his family and 
her/his social context.10-12 Previous studies have 
shown that the psychosocial outcomes following 
BRCA1/2 testing vary according to the previous 
individual and family experiences of each patient 
as well as with the time elapsed after disclosure 
of the test result.10-19 Distress increases shortly after 
receiving results and returns to pretesting levels 
over time. Time is relevant not only for carriers 
but also for individuals with inconclusive results 
and non-carriers of BRCA1/2 mutations.14,16 The 
possibility of positive results of BRCA1/2 testing 
eliciting anxiety, depression or guilt was previously 
described.14,16,20,21 Possible causes are the possibility of 
having transmitted the cancer predisposing variant to 
their offspring and due to other family, marital and 
reproductive issues,11-13 as well as issues of access to 
health care and insurance. There is little information, 
however, about that impact emotional distress may 
have in the understanding and adherence to specific 
risk-reducing management plans proposed to BRCA 
carriers. A previous study reported that not only 
breast cancer genetics knowledge but also cancer-
-specific distress were significantly associated with 
adherence to recommended risk reducing plan.22 
Women are overrepresented in previous studies 
of distress, and even studies that included men 
had very low numbers of confirmed carriers.23,24 
With the recognition that BRCA1/2 men also have 
higher cancer risks,24 and need specific surveillance 
guidelines,25 the number of male candidates for BRCA 
genetic screening is increasing. More information is 
needed about the psychological impact of BRCA1/2 
testing in male carriers.
Instruments for identification of the impact of cancer 
risk assessment have been previously described.26, 27 
Distress, a vital measure in psycho-oncology,28-31 was 
also studied and patients with a positive BRCA1/2 
test result had distinct questionnaire results from 
patients with negative or inconclusive tests.26 For 
this subgroup of individuals, a reliable instrument 
allowing for the systematic identification of distress 
is needed to manage adequate psychosocial support. 
In this study, our primary objectives were to develop 
and validate a short instrument, possible to apply by 
telephone, to evaluate the prevalence of distress one 
month after the disclosure of a positive BRCA1 or 
BRCA2 test result. The instrument included questions 
about risk perception. An exploratory objective was 
the analysis of predictive factors for clinically relevant 
distress, in this population.
 Materials and Methods
Institutional approval – This study was approved 
by the Ethics Committee of Instituto Português de 
Oncologia de Lisboa Francisco Gentil (Study number 
IPOLFG, UIC/634). 
Study design and participants – This was a pros-
pective, cross-sectional study conducted in the family 
cancer clinic of the Instituto Português de Oncologia 
de Lisboa, a tertiary cancer centre, that provides 
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counselling for several public and private health 
institutions of Southern Portugal, under a multidis-
ciplinary program. The study population comprised 
all consecutive BRCA1/2 carriers identified from April 
2011 to April 2014 aged 18 and older, capable of 
expressing free consent, regardless of gender and 
previous cancer history. All subjects had received 
pre- and post-testing genetic counselling and were 
carriers of a deleterious BRCA1/2 mutation. 
Study procedures – Subjects were invited to par-
ticipate in this study, after the post-test counselling 
visit. Those willing to participate signed the informed 
consent form. A structured telephone interview was 
conducted by the research nurses one month after 
disclosure of the positive BRCA1 or BRCA2 test 
result. Research genetic nurses were trained on 
competences in communication through telephone 
interviews by a certified psychologist. 
Patient measurements – Socioeconomic and demo-
graphic data were collected from patients’ clinical 
notes. Variables assessed were age, gender, marital 
status, number of children and occupational status.32
Distress Thermometer (DT)- – This is a universal 
measure to evaluate distress in cancer patients. It 
is a single-item, 11-point range scale (ranging from 
0 “no distress” to 10 “extreme distress”), used as 
a self-report measure of psychological distress.33-35 
DT is validated in the Portuguese population.35 
The symptoms list was not used since it would be 
difficult to use it by telephone. During telephone 
interviews patients were asked to give the number 
(0-10) that best described how distressed they had 
been in the previous week, including the day of the 
interview. In the Portuguese population, a DT score 
above 4 indicates clinically relevant distress level.35 
Distress and Risk Perception Questionnaire (DRP) 
– DRP is a 13 item self-report measure that evaluates 
two dimensions: psychological distress and risk 
perception concerning disease status and indivi-
dualized risk-management plan. We developed the 
DCRP because there was the need to have a short 
questionnaire that could be easily answered through 
a telephone interview. Psychological distress in DRP 
comprises three scales: anxiety, depression and loss 
of emotional control. Each scale has 3 items, all 
with a 5 position Likert type response (appendix 
1). These 9 items correspond to a short version of 
the Mental Health Inventory Questionnaire (MHI) 
that has been used to evaluate psychological distress 
in populations without a psychiatric diagnosis (24 
items) and emotional well-being (14 items). MHI is 
validated for the Portuguese population.36 The other 
dimension of DRP, risk perception concerning disease 
status and individualized risk-management plans,6 
comprises 4 items also with a 5 position Likert type 
response each (appendix 1). In DRP each item was 
scored in a scale ranging from 1 to 5; the global 
score for each dimension was obtained by the sum 
of the scores from the respective items. Distress 
score ranges from 9 “no distress” to 45 “extreme 
distress” and the risk perception score ranges from 
4 to 20, with higher values corresponding to better 
risk perception.
Pre-test phase: validation of DRP questionnaire – 
We conducted a pre-test phase between September 
2010 and March 2011 in a sample of 21 individuals to 
assess the internal consistency and construct validity 
of DRP. Cronbach’s alpha was calculated for each 
subscale and dimension separately and all obtained 
values were above 0.80, showing adequate internal 
consistency. Spearman rank correlation coefficient 
was used to evaluate the convergent and discriminant 
validity. Convergent validity was deemed to be 
acceptable if convergent correlations (i.e., correlation 
between items that should theoretically be related to 
each other) were above 0.4. For discriminant validity 
there should be a difference of at least 10 decimal 
points between the convergent and discriminant 
correlations (i.e., correlation between items that 
should not be related). The results obtained were 
similar to the ones reported for the original longer 
Portuguese version of the MHI questionnaire36 and 
were in compliance with the pre-specified acceptance 
conditions. Concurrent validity was evaluated by 
comparison to DT with reliable results (Spearman’s 
rank correlation coefficient = 0.86). A DRP distress 
score above 21 was the optimal cut off value found 
by Receiver Operating Characteristic (ROC) curve 
analysis for identification of individuals with clinically 
relevant distress (sensitivity=100%; specificity=91%).
Statistical methods
Descriptive statistics was used for socio-demogra-
phic and clinical characterization of the sample and 
for description of the distress and risk perception 
score measures. The correlation between risk per-
ception and distress levels was evaluated using the 
Spearman rank correlation coefficient. We conducted 
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an exploratory analysis using logistic regression in 
order to identify independent predictors of clinically 
relevant distress (DT score>4 or DCRP score dis-
tress>21). The factors evaluated were age (≤50 vs 
>50 years-old), gender, prior cancer diagnosis (yes 
vs no), type of genetic screening (index proband 
vs other familial), and offspring (yes vs no). The 
unadjusted OR refer to the results of the univariate 
logistic regression analysis. Factors with statistically 
significant associations (p<0.10) on univariate analy-
sis were then analysed using multivariable logistic 
regression to identify independent risk factors. We 
calculated the Variance Inflation Factors (VIF) to 
check for multicollinearity and the Durbin-Watson 
(DW) statistics to test for correlated residuals. In 
all cases VIF values were below four and the DW 
statistics were close to two with non-significant asso-
ciated p-values, thus indicating no multicollinearity 
or autocorrelation issues. All tests were two-sided 
and a significance level of 5% was considered unless 
otherwise specified. As there were no missing values 
no imputation methods were required. The analysis 
was conducted using R.37
 Results
One hundred and forty nine out of 177 eligible 
new consecutive identified BRCA1/2 carriers were 
included in this study. Reasons for exclusion were 
logistical reasons (n=22), death (n=2), patient refusal 
(n=1) and progressive symptomatic disease preven-
ting participation (n=3). 
Socio-demographic and clinical characterization 
Table 1 shows the socio-demographic and clinical 
characteristics of the 149 individuals included in the 
study. There was a predominance of women (81%). 
The overall median age at the time of inclusion in 
the study was 43 years, being 42 (range: 21-74) in 
women and 44 (range: 25-73) years in men. 
Sixty-seven individuals (45%) had a previous 
cancer diagnosis, 14 more than 5 years prior to 
inclusion in the study and the remaining 53 within 
a 5 year period. The remaining 82 carriers (55%) 
were healthy at risk and had previously consented 
on pre-symptomatic BRCA1/2 diagnosis. Fifty four 
carriers (36%) had consented on genetic BRCA1/2 
screening as index patients (the first family relative 
to be tested in one family) and the others as relati-
ves of patients previously tested and positive for a 
BRCA1/2 mutation. Only 42 participants (28%) had 
no offspring and most (68%) were professionally 
active. Regarding occupational status only 9% were 
non-qualified workers.
Evaluation of distress and risk perception
Table 2 presents the descriptive summary of the 
scores concerning the DT and all dimensions and 
subscales of the DRP measure instrument. The mean 
observed distress scores were 3.1 (SD 2.7) and 20.1 
(SD 7.9) for DT and DRP instruments, respectively. 
Fifty percent of the individuals reported a DT score≤2 
and a distress score measured by DRP≤18; in both 
cases these values are below the cut-off for clinically 
relevant distress levels (above 4 for DT and above 21 
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Type of genetic screening
Index patient
Relatives of index patients
54 (36%)
95 (64%)
a  Profession related to military, political and management positions and 
scientific activities [10].
b  Civil service and commercials, administrative, security, qualified agriculture, 
forest and fishing workers, qualified industry workers [10].
c  Non-qualified workers and machine and technical operators [10].
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for DRP). Forty-two (28%) and 60 (40%) individuals 
were found to have clinically relevant distress when 
evaluated by the DT and DRP scale, respectively. 
Those carriers were evaluated in the clinic and 28 
of them (19%) were confirmed as having criteria for 
specialized psychological-social support, and were 
appropriately referred.
As for risk perception observed in our sample 
(mean 18.7; SD 1.9; median 20) (Table 2) no signi-
ficant correlation could be demonstrated between 
the risk perception and the distress levels, either 
evaluated by DRP (correlation coefficient=-0.047; 
p-value=0.5731) or DT (correlation coefficient= 0.041; 
p-value=0.6202). 
Table 2 – Descriptive summary for Distress and Risk Perception
Dimensions and subscales Mean SD Min Max Median IQR
Distress – DT 3.1 2.7 0 10 2 [1-5]
Distress – DRP 20.1 7.9 9 41 18 [13-25]
Anxiety 7.4 2.8 3 15 7 [5-9]
Depression 6.5 2.9 3 15 6 [4-8]
Loss of emotional control 6.3 2.8 3 14 6 [4-8]
Risk Perception – DRP 18.7 1.9 11 20 20 [18-20]
DT – Distress Thermometer; DRP - Distress and Risk Perception Questionnaire; SD – Standard deviation; IQR – Interquartile range [25% quartile – 75% quartile]
Minimum and maximum possible scores for each dimension/subscale: Distress – DT: 0-10; Distress – DRP: 9-45; Anxiety: 3-15; Depression: 3-15; Loss of 
emotional control: 3-15; Risk Perception about individualized risk-reducing plans: 4-20.
Table 3 – Predictive factors for clinically relevant distress scores during the month after disclosure of a positive BRCA1/2 test (univariate 
analysis)
Variable n











Male 29 4 (14%) 0.35
(0.10-0.97)
0.0424 5 (17%) 0.25
(0.08-0.64)
0.0032
Female (ref) 120 38 (32%) 1 55 (46%) 1
Age
>50 years 46 15 (33%) 1.36
(0.63-2.89)
0.4264 18 (39%) 0.93
(0.45-1.89)
0.8497
≤50 years 103 27 (26%) 1 42 (41%) 1
Prior cancer diagnosis
Yes 67 20 (30%) 1.16
(0.56-2.38)
0.6837 30 (45%) 1.41
(0.73-2.73)
0.3107
No 82 22 (27%) 1 30 (37%) 1
Type of genetic screening
Index 54 20 (37%) 1.95
(0.94-4.07)
0.0730 26 (48%) 1.67
(0.84-3.30)
0.1404
Relative 95 22 (23%) 1 34 (36%) 1
Offspringa
Yes 106 32 (30%) 1.38
(0.62-3.27)
0.4379 46 (43%) 1.53
(0.73-3.31)
0.265
No (ref) 42 10 (24%) 1 14 (33%) 1
DT – Distress Thermometer; DRP – Distress and Risk Perception Questionnaire 
a  One subject without information concerning offspring was not included in this analysis.
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Exploratory analysis of the predictors for clinically 
relevant distress
In preliminary descriptive analysis distress scores 
were consistently higher in women than in men and 
in index patients as opposed to non-index cases 
(Figures 1A-B and 1C-D). Nevertheless, in univariate 
analysis, gender was the only factor significantly 
associated with clinically relevant distress, with a 
reduction of 65% to 75% in the odds in men compa-
red to women (DT instrument: Unadjusted OR=0.35; 
95%CI 0.10-0.97. DCRP instrument: Unadjusted 
OR=0.25; 95% CI: 0.08-0.64) (Table 3). A trend for 
an association between type of genetic screening and 
clinically relevant distress was observed for DT, with 
an increase of 95% of the odds of distress in index 
cases compared to non-index cases (Unadjusted 
OR=1.95; 95% CI 0.94-4.07) (Table 3). 
In order to control for a potential confounding 
effect between gender and type of genetic screening 
(in females 43% were index cases and in males only 
10%) and prior cancer diagnosis (52% in females and 
17% in males) we also conducted a multivariable 
analysis considering these variables (Table 4). All 
the other variables were well balanced between 
genders. This multivariable analysis confirmed gender 
(DCRP score) as an independent factor for clinically 
relevant distress after adjusting for type of genetic 
screening and prior history of cancer (OR male vs 
female=0.26; 95% CI 0.08-0.71). In the multivariable 
analysis based on the DT score, type of genetic 
screening was an independent factor (OR index vs 
familial=3.93; 95% CI 1.13-18.37) and there was a 
trend for lower odds of distress in men (OR male 
vs female=0.37; 95% CI 0.10-1.09).
 Discussion
In this study the prevalence of clinically relevant 
distress during the month after disclosure of a positive 
BRCA1/2 test result was 40%. Female gender and 
undergoing index testing were identified as predictive 
Fig 1A – Boxplot of Distress Thermometer (DT) distress score by 
gender
Fig 1B – Boxplot of Distress and Risk Perception Questionnaire 
(DRP) distress score by gender
Fig 1C – Boxplot of Distress Thermometer (DT) distress score by 
type of genetic screening
Fig 1D – Boxplot of Distress and Risk Perception Questionnaire 
(DRP) distress score by type of genetic screening
Horizontal dotted lines indicate the cut-off values above which the distress level becomes clinically relevant. 
FALTA
FALTA FALTA
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factors for distress. We also observed that even 
distressed carriers were able to retain information 
about individualized risk reducing plans. 
We developed a new measure, the DRP, given 
the lack of available instruments validated for the 
Portuguese population evaluating both distress and 
risk perception. There is also a need for short but 
reliable questionnaires that can be applied during 
telephone interviews. Indeed, other questionnaires 
are longer and not so easily applied by digital means, 
although they measure other dimensions besides 
Distress.26, 27 
The prevalence of clinically relevant distress dro-
pped to 28% when considering the results obtained 
with the DT instrument. The apparent discrepancy 
between DT and DRP is related either with the 
different sensitivity of the measures or with the 
different time periods these instruments refer to. 
Interviews were conducted one month after test 
disclosure but DT evaluates distress during the 
last 7 days while DRP evaluates distress for the 
whole month after test disclosure. Our results are 
in line with the previous observations that distress 
is influenced by time elapsed after test disclosure, 
decreasing to pre-test levels with time.10, 14, 16 Even 
though we did not study pre-test levels, our data 
suggests that as much as 40% of carriers experienced 
clinically relevant distress at any time during the 
first month after disclosure of the test result. This 
proportion decreases to 28% in the last 7 days of 
the covered timeframe. Although most of these 
carriers declined psychological support, 28 (19%) 
were referred to psychological observation after 
review of these results.
Our sample consisted of women, aged less than 51 
years, actively employed and with at least one child. 
Concerning predictive factors for distress we found 
some differences between the DT and DRP: when 
analyzing DRP, female gender was the only factor 
significantly associated with distress after adjusting 
for type of genetic screening and for prior cancer 
diagnosis. This may be explained by the known 
association of BRCA1/2 gene mutations with female 
cancers, together with their impact on femininity.16 
With DT besides female gender, a trend for a higher 
distress among index patients was also observed. 
These predictive factors for distress measured with 
DT (index cases and female gender) may be related 
with the time needed to integrate the complex 
genetic information in the individual and family 
dynamics. The emotional impact of an adverse life 
event such as the disclosure of a high cancer risk 
arouses coping strategies of avoidance.38-40 These 
strategies predominate during the early stage when 
the emotional intensity of the life event is highest.41 
Previous data reveal that, after a few weeks, these 
mechanisms lose their dominance, and other factors 
such as the search for information and the need to 
share it with others start to emerge.10 Index cases 
should communicate or allow communication of 
information about the genetic risk to relatives.42 This 
might be a possible explanation for the association 
found between type of genetic screening and distress 
in DT (evaluates distress during the last week in a 




Distress measure instrument DT
Model B 
Distress measure instrument DRP
OR 95%CI p OR 95%CI P
Gender
Male 0.37 0.10-1.09 0.0960 0.26 0.08-0.71 0.0131
Female 1 1
Prior cancer diagnosis
Yes 0.44 0.07-1.15 0.1106 0.79 0.27-2.19 0.6574
No 1 1
Type genetic screening
Index 3.93 1.13-18.37 0.0468 1.57 0.55-4.69 0.4026
Relative 1 1
DT – Distress Thermometer; DRP – Distress and Risk Perception Questionnaire 
Model A: Variance Inflation Factors: gender=1.06, prior cancer diagnosis=3.31, type genetic screening=3.31; Durbin-Watson statistic=2.05, p-value=0.766
Model B: Variance Inflation Factors: gender=1.06, prior cancer diagnosis=2.34, type genetic screening=3.32; Durbin-Watson statistic=2.05, p-value=0.766
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4 week period) but not in DRP (which evaluates 
distress during the whole 4 week period). Effective 
risk perception may have contributed to overcome 
the lower proportion of clinically relevant distress 
observed when using DT.43 Nevertheless, we could 
not demonstrate any significant correlation between 
risk perception and distress, probably because there 
were no identifiable patients with low level of risk 
perception. 
As previously described14,16,20 cancer specific dis-
tress in this population probably depends on the 
concerns about medical surveillance, prophylactic 
surgeries, communication of results to family mem-
bers and reproductive decisions. Transmission of a 
clear risk reducing plan may help to divert the focus 
from negative information (being the carrier of a 
characteristic associated with high risk for cancer) 
to coping.42 
No difference in distress was observed between 
cancer survivors and individuals undergoing pre-
-symptomatic testing. This may be explained by the 
sense of familiarity with cancer8,42 observed in some 
BRCA1/2 families: even non-affected individuals deal 
with cancer in their close relatives (mothers, sisters, 
aunts and cousins) since very young ages. This 
familiarity may lead to the acquisition of adaptive 
mechanisms and skills that help to deal better with 
cancer related information,43 like, in this specific 
setting, a positive BRCA1/2 test result.
Few studies with small numbers have evaluated 
the impact of BRCA1/2 testing in men. Both distress 
and self-perception of risk have been reported as 
increased in male BRCA1/2 carriers.24,44 Cancer risks 
have been recognized for these carriers4,24 but, with 
the possible exception of prostate cancer25 clear evi-
dence is lacking concerning benefits of surveillance. 
To our knowledge, this study is the first description 
of the association between gender (being lower for 
men) and distress after the disclosure of a positive 
BRCA1/2 test. Distress was previously identified38 
in male BRCA1/2 carriers up to 4 years after test 
disclosure, but data was retrospectively collected.23 
Our data adds to evidence that males have specific 
needs regarding genetic testing.21, 44 
 Conclusion
In conclusion, we validated a short questionnaire 
easy to implement in clinical practice to screen for 
distress and risk perception after disclosure of a 
BRCA1/2 positive test. No correlation was observed 
between risk perception and the level of distress. 
Being a female and an index patient were the only 
factors associated with clinically relevant distress. 
As a future recommendation, and besides the 
implementation of the DRP instrument in the routine 
practice of genetics clinics, the authors reinforce 
the need for larger prospective studies, that should 
address if short term distress predicts adverse psycho-
logical outcomes, in individuals that test positive for 
BRCA1/2 testing.
The strengths of our study are its prospective 
design and the inclusion of a consecutive sample, 
minimizing selection bias. The shorter scale for Dis-
tress identification was validated by phone, allowing 
for widespread use in a time when candidates for 
cancer genetic testing are increasing and posing 
a huge burden on genetic and family cancer risk 
services. 
The limitations of this study are the small sample 
of BRCA1/2 carriers included in the validation phase 
and the single-center methodology. Nevertheless, 
the pre-validation sample was representative of all 
the participants included, and data were collected 
by the same trained health professionals during 
structured interviews throughout the whole study. 
The generalizability of this single-center research may 
not be compromised, because our center is a referral 
center for genetic BRCA screening in our country. 
Long term distress was not measured neither the 
association between short and long term distress, 
but that analysis was beyond the scope of this study.
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 Annex 1 
Distress and risk perception questionnaire (drp)
Section 1. Distress 
The questions below are about worries that you may have had after receiving your genetic test results. 
Please answer every question indicating whether you have experienced each emotion always, often, 







1.  During the past month, how often did you feel nervous or 
uneasy due to the result of the genetic diagnosis?
2.  During the past month, how often did you feel anxious or 
worried due to your test results?
3.  Did you feel depressed during the past month?
4.  During the past month, how often did you feel tense and angry?
5.  How often in the past month did you feel emotionally stable? 
6.  During the past month how often did you feel that your life 
projects were in jeopardy?
7.  How often, during the past month, did you feel that everything 
that happened was the opposite of what you wished?
8.  In the past month how often did you feel down?
9.  During the past month, have you been, or have you felt under 
great pressure or stress?
Section 2. Risk Perception
The questions below are about the information you were provide with about cancer risk in your family 
and about possible measures of individual risk management. Please answer every question indicating 











10.  Did you perceive the cancer risk related with your positive 
test result?
11.  Did you understand how important it is to have an indivi-
dualized risk reducing plan?
12.  Did you retain information about the risk-reduction strategies 
available (clinical and radiological surveillance, other exams 
and preventive surgeries)?
13.  Do you consider the information provided by the team to 
be adequate?
